Jubak Picks
Trick or trend: Whither gold? As of June 30 Warren Buffett was a buyer
Our regular (or occasional or perhaps occasionally regular) Friday series (actually running on Saturday this week) Trick or Trend looks at what might (or might not) be emerging investible trends. Exclusively on JAM. This post won't run anywhere else. Ever.Granted it's...
Adding West Pharmaceutical Services to Jubak Picks Portfolio on rotation back to momentum winners
What a difference 72 hours can make. Just a few days ago I was looking to find consumer/cyclical/"re-opening dependent" shares as the stock market looked to be rotating away from recent technology and momentum leaders and toward beaten down shares that would climb...
Gold and silver take another step toward excess
We've been here before. With gold and silver we're at that stage in a huge rally where Wall Street analysts rush to increase their target prices in order to keep ahead of the market and where the number of posts urging investors to get in now--And here's...
Ericsson is my 5G network pick
Ericsson (ERIC) has been piling up the contract wins for 5G networks. That's the future--which is why I'm recommending buying this ADR in my Jubak Picks Portfolio today. If you want to ride the transition to 5G telecommunications network, this is the best horse to...
Incyte beats on earnings, revenue–but drops on lack of improved guidance
Shares of biotech Incyte (INCY) were down 2.60% as of 1:30 p.m. Tuesday on earnings and revenue that stomped Wall Street projections. The company reported second quarter adjusted earnings of $1.24 a share versus Wall Street projections for 50 cents a share. Earnings...
Microsoft’s growth disappoints Wall Street in yesterday’s earnings report
Shares of Microsoft (MSFT) were down 4.35%at the close today in spite of the company's strong beat of Wall Street projections for the company's fiscal fourth quarter that ended on June 30. The company reported earnings of $1.46 a share, versus Wall Street projections...
Jubak Picks member Xylem gains 8.97% on upgraded guidance ahead of earnings
Just a reminder today from Xylem (XYL) of why the company is one of the best investments in trends in the water market. The shares moved up 8.97% ahead of the release of second quarter earnings on July 30, 2020 to close at $73.38. Today, July 14, I'm raising my target...
Selling Salesforce out of my Jubak Picks Portfolio as shares hit target price
Salesforce (CRM) has hit my $185 a share target price. I'm selling it out of my Jubak Picks Portfolio with a 37.42% gain since I added that position back on November 1, 2018. Why sell rather than up the target price? A couple of four reasons for what amounts to taking...
Raising my target price on Incyte to $120 a share after 58.5% gain in last 3 months
I admit it. I feel silly talking about price targets and valuations in this market. After all everything is just going to the sky. Infinity and Beyond!!! But, as silly as I may feel, I don't think the gods of investing have repealed the laws of valuation. At some...
Bonus Special Report: 5 More Stocks for after the Coronavirus–fourth pick Visa
Just about everybody agrees that the world after the coronavirus pandemic and recession will look very different. And from what I've read every stock market guru worth his or her smart phone agrees that buying the stocks of companies that are "attuned" to that...Jim’s Stock Alerts
Download Jim’s eBook for Free
